A2 Biotherapeutics Inc. is recruiting patients for a N/A clinical trial testing CAR-T cell therapy for mesothelioma.
The trial, designated NCT04981119, aims to enroll up to 200 participants at 16 sites, including locations in Arizona, California, Florida.
About the Study
Objective:
To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant’s own T cells for future use to make CAR T-Cell therapy for their disease treatment.
Design:
This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant’s tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant’s cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.
Treatment Approach
This trial uses genetically engineered T cells that target mesothelin on mesothelioma cells.
Key trial details:
- Phase: N/A
- Sponsor: A2 Biotherapeutics Inc.
- Enrollment target: 200
- Status: RECRUITING
Why This Trial Matters
CAR-T cell therapy has revolutionized treatment for blood cancers, and researchers are working to adapt this approach for solid tumors like mesothelioma.
Study Locations
The trial is recruiting at:
- Banner Health, Arizona
- Mayo Clinic Hospital, Arizona
- City of Hope, California
- University of California San Diego, California
- Stanford University, California
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening